Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.75
Bid: 42.00
Ask: 43.50
Change: -2.60 (-6.05%)
Spread: 1.50 (3.571%)
Open: 42.75
High: 40.40
Low: 40.40
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Thu, 25th Mar 2021 15:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

----------

Ten Entertainment Group PLC - Cranfield, England-based tenpin bowling operator - Nick Basing will step down as chair in September, after 6 years in the role and 12 with the company and its predecessor Essenden. Company has started the process of finding a replacement.

----------

Emmerson PLC - Khemisset potash project in northern Morocco - Mark Connelly retires as non-executive chair at general meeting, during which shareholders also approved Emmerson's move to AIM from the London Main Market, effective from Friday. Non-Executive Director James Kelly is promoted to independent non-executive chair.

----------

Ceres Power Holdings PLC - Horsham, West Sussex-based solid oxide fuel cell developer - Hires Tudor Brown as independent non-executive director, starting Thursday next week. Brown was among the founders of computer chip designer ARM Holdings PLC and served ARM as chief technology officer and chief operating officer. He is on the board of Hong Kong-listed personal computer and smart phone maker Lenovo Group Ltd.

----------

Atalaya Mining PLC - copper and silver mining in Spain - Jose Sierra will retire as an independent non-executive director on Wednesday next week, having served on the Atalaya board since 2011.

----------

Euromoney Institutional Investor PLC - London-based business media and events - Lorna Tilbian steps down as non-executive director, effective immediately, "to spend more time focusing on her other business interests".

----------

Biome Technologies PLC - Southampton, Hampshire-based biodegradable plastics and radio frequency systems - Hires Simon Herrick as non-executive director, joining immediately. Herrick is a non-executive director of London listings Ramsdens Holdings PLC and FireAngel Safety Technology Group PLC. As an executive, Herrick was chief financial officer for a number of companies, including department store chain Debenhams and Blancco Technology Group PLC. He will replace Michael Kayser as chair of the audit and remuneration committees when Kayser retires from the board at the Biome's annual general meeting on April 21.

----------

Avacta Group PLC - Wetherby, England-based developer of cancer immunotherapies - Mike Owen steps down as non-executive director, effective immediately, but remains chair of Avacta's scientific advisory board.

----------

Arrow Global Group PLC - European investor and alternative asset manager of loan portfolios - Appoints Davide Stecchi as managing director of Underwriting to lead the Arrow Capital Management underwriting team. Prior to joining Arrow, Stecchi spent 7 years at Hudson Advisors.

----------

Tirupati Graphite PLC - London-based graphite producer with operations in Madagascar and India - Strengthens its team across its three business units to support its growth. Appoints Biswal as head of the Tirupati Graphene & Mintech Research Centre. Names Sathpathy as an advisor to the company, specially focussed on application of graphene in aluminium manufacturing smelters and graphene aluminium composites development. Appoints Dash, who is also focused on graphene engineering science, to board.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
30 Jul 2018 12:48

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to help fund new drug development is to place at

Read more
24 Jul 2018 11:26

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, professor of developmental, chemical and molecular Biology at Tufts University School of Medicine in Boston.

Read more
11 Jun 2018 10:48

Avacta Appoints Ex-Immunocore Boss Eliot Forster As Chairman

LONDON (Alliance News) - Biotechnology firm Avacta Group PLC said Monday it appointed ex-Immunocore Ltd boss Eliot Forster as its non-executive chairman.Forster served as Immunocore CEO in

Read more
29 Mar 2018 13:58

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive be

Read more
13 Mar 2018 14:26

DIRECTOR DEALINGS: Avacta Chief Executive Officer Smith Buys Shares

LONDON (Alliance News) - Avacta Group PLC said its Chief Executive Officer Alastair Smith bought shares in the biotechnology company in transaction on Tuesday.Smith at

Read more
20 Jan 2017 10:17

Avacta expects licensing deal for therapeutics product in 2017, order book swells

(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled. In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which alo

Read more
7 Nov 2016 09:41

Avacta Adds Cancer Stem Cell Specialist Evan To Scientific Board

Read more
2 Nov 2016 15:59

Avacta announces collaboration with Memorial Sloan Kettering Cancer Center

(ShareCast News) - Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy. The AIM-traded firm said CAR-T immunotherapy is a form of cancer treatment i

Read more
17 Oct 2016 10:54

Avacta Group narrows loss as revenues rise

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations. The AIM-traded company said it was well funded at period end, with cash balances o

Read more
22 Sep 2016 15:56

Avacta reveals positive results from Affirmer studies

(ShareCast News) - Affimer biotherapeutics and research reagents developer Avacta Group announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules on Thursday. The AIM-traded company said the results meaningfully de-risk the development of the technolo

Read more
22 Sep 2016 07:57

Avacta Reports Good First Results From Affimer Pre-Clinical Trials

Read more
10 Aug 2016 09:28

Avacta collaboration programme gets £3.8m grant

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council. The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents,

Read more
10 Aug 2016 07:43

Avacta-Leeds University Partnership Gets GBP3.8 Million Grant

Read more
3 Aug 2016 15:02

Avacta granted European patent for Affimer technology

(ShareCast News) - European and US regulators handed down further patent decisions in favour of Avacta´s Affimer biotherapeutics and research reagents, helping the company to consolidate its intelectual property portfolio. In Europe, authorities granted the Life Sciences group the main patent for it

Read more
1 Aug 2016 14:16

Avacta revenue in line with forecasts, but losses mount

(ShareCast News) - Life sciences company Avacta said on Monday that revenue for the year to the end of July grew by around 19% but losses nearly doubled due to a change in accounting policy. In a pre-close trading update ahead of its preliminary results for the year to the end of July, Avacta said r

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.